# NCT04821622 (NCT04821622)

> Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04821622
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Pfizer
- Conditions: Prostate Cancer
- Interventions: talazoparib plus enzalutamide; Placebo plus enzalutamide
- Enrollment: 599
- Primary outcome: radiological Progression-Free Survival

## Commentary we found

- X threads: 83
- YouTube: 75
- Podcasts: 53
- X videos: 6

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=nct04821622

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04821622", "email": "<work email>"}; the inbox owner confirms by the emailed link.